Cytophage Announces Closing of Non-Brokered Private Placement and Filing of Q3 Financials

Executive Summary

• Cytophage Technologies closed the remainder of its previously announced non‑brokered private placement, raising an additional $198,000 in gross proceeds for a total of $1.2 million.
• The offering consisted of 990,000 Units at $0.20 each; each Unit includes one common share and half of a warrant to purchase an additional share at C$0.40 for 24 months.
• Net proceeds will be used to advance phage technology in human health, animal health, food security, and general corporate purposes; the company also filed its Q3 2025 financial results on SEDAR.

Key Details

• Total gross proceeds: $1,200,000 (including prior tranche).
• Additional amount raised in this closing: $198,000.
• Units issued: 990,000 Units at $0.20 per Unit.
• Unit composition: 1 common share + ½ warrant (full warrant = right to purchase 1 additional share at C$0.40).
• Warrant term: exercisable for 24 months from issuance; acceleration right if TSX‑V average price ≥ $0.60 for 10 consecutive trading days.
• Finder’s fees: $4,200 cash plus 21,000 broker warrants on the same terms as offering warrants, subject to Exchange approval.
• Holding period: All securities issued are subject to a four‑month hold period per TSX Venture Exchange rules.
• Use of proceeds: Advancement of cutting‑edge phage technology for human health, animal health, food security, and general corporate purposes.
• Regulatory condition: Closing remains subject to TSX Venture Exchange approval.
• Disclosure: Securities not registered under U.S. securities laws; offering not available in the United States absent exemption or registration.
• Additional filing: Company announced filing of Q3 2025 financial statements and MD&A on SEDAR (sedarplus.com).

Notable Quotes

(No direct quotes were provided in the release.)